ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

Jul 25, 2019
1 min read

Geneva, Switzerland, July 24, 2019 – Recombinant monoclonal antibody H225, a blocker of JAM-C (Junction Adhesion Molecule C) generates impressive efficacy data in a Mantle Cell Lymphoma animal model.

Abologix obtains funding from the KICK FUND

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

Comments

Back to Top